Stay updated on Pembrolizumab and Doxorubicin in Sarcoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Doxorubicin in Sarcoma Clinical Trial page.

Latest updates to the Pembrolizumab and Doxorubicin in Sarcoma Clinical Trial page
- CheckyesterdayChange DetectedThe page now shows Revision: v3.5.4 at the bottom, replacing Revision: v3.5.3, indicating a recent site update or release without modifying the study content.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe webpage’s footer revision version is updated from v3.5.2 to v3.5.3, reflecting a site release rather than a change to the trial record content.SummaryDifference0.1%

- Check30 days agoChange DetectedSite revision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check58 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3.SummaryDifference0.1%

- Check66 days agoChange DetectedFooter now displays Revision: v3.4.3 and the previous Revision: v3.4.2 label was removed.SummaryDifference0.1%

- Check94 days agoChange DetectedAdded Revision: v3.4.2 and removed the government funding lapse notice, which are minor site maintenance updates that do not affect the study details or core content on this page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab and Doxorubicin in Sarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Doxorubicin in Sarcoma Clinical Trial page.